# Alzamend Neuro Inc. (ALZN)

Source: https://www.quantisnow.com/company/ALZN
Generated: 2026-11-16T20:14:29.992Z

- Ticker: ALZN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001677077
- Website: alzamend.com

## About

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

## Latest ALZN news and filings

- 2026-11-10 21:30 UTC [SEC Form 8-K] [Amendment: Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amendment-alzamend-neuro-inc-filed-sec-form-8-k-entry-into-6784357)
- 2026-10-09 10:02 UTC [SEC Form RW filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-alzamend-neuro-inc-6742298)
- 2026-09-29 10:30 UTC [SEC Form 8-K] [Alzamend Neuro Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alzamend-neuro-inc-filed-sec-form-8-k-regulation-fd-disclosure-6728290)
- 2026-09-16 12:00 UTC [Alzamend Neuro Regains Compliance with Nasdaq Listing Standards](https://www.quantisnow.com/insight/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-6716950)
- 2026-09-10 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-alzamend-neuro-inc-6711827)
- 2026-08-31 10:00 UTC [Insider Buy] [Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-ault-milton-c-iii-bought-110965-worth-of-6698971)
- 2026-08-31 10:00 UTC [Insider Buy] [Amendment: Director Ault Milton C Iii bought $110,965 worth of shares (110,388 units at $1.01) (SEC Form 4)](https://www.quantisnow.com/insight/amendment-director-ault-milton-c-iii-bought-110965-worth-of-6698966)
- 2026-08-31 10:05 UTC [SEC Form 4] [Director Ault Milton C Iii sold $3,116 worth of shares (2,000 units at $1.56), closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ault-milton-c-iii-sold-3116-worth-of-shares-6698959)
- 2026-08-28 20:30 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-alzamend-neuro-inc-6698521)
- 2026-08-21 20:30 UTC [SEC Form S-1] [SEC Form S-1 filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-alzamend-neuro-inc-6691462)
- 2026-08-21 01:18 UTC [SEC Form 4] [Amendment: SEC Form 4 filed by Director by deputization Hyperscale Data, Inc.](https://www.quantisnow.com/insight/amendment-sec-form-4-filed-by-director-by-deputization-hyperscale-6690632)
- 2026-08-21 01:17 UTC [SEC Form 3] [Amendment: SEC Form 3 filed by new insider Hyperscale Data, Inc.](https://www.quantisnow.com/insight/amendment-sec-form-3-filed-by-new-insider-hyperscale-data-6690631)
- 2026-08-20 12:00 UTC [Conference Announcement] [Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC](https://www.quantisnow.com/insight/alzamend-neuros-phase-12a-lithium-neuroimaging-data-accepted-for-poster-6689447)
- 2026-08-18 12:00 UTC [Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain](https://www.quantisnow.com/insight/alzamend-neuros-phase-12a-lithium-imaging-data-accepted-for-oral-6685909)
- 2026-08-05 01:38 UTC [SEC Form 4] [SEC Form 4 filed by Director by deputization Hyperscale Data, Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-by-deputization-hyperscale-data-6663537)
- 2026-08-05 01:37 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hyperscale Data, Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hyperscale-data-inc-6663536)
- 2026-08-05 01:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Ault Milton C Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ault-milton-c-iii-6663534)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Horne William B.](https://www.quantisnow.com/insight/sec-form-5-filed-by-horne-william-b-6663505)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Gustafson Mark](https://www.quantisnow.com/insight/sec-form-5-filed-by-gustafson-mark-6663504)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Oram Jeffrey](https://www.quantisnow.com/insight/sec-form-5-filed-by-oram-jeffrey-6663503)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Nisser Henry Carl](https://www.quantisnow.com/insight/sec-form-5-filed-by-nisser-henry-carl-6663502)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Katzoff David J](https://www.quantisnow.com/insight/sec-form-5-filed-by-katzoff-david-j-6663501)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Jackman Stephan](https://www.quantisnow.com/insight/sec-form-5-filed-by-jackman-stephan-6663500)
- 2026-08-05 01:00 UTC [SEC Form 5] [SEC Form 5 filed by Ault Milton C Iii](https://www.quantisnow.com/insight/sec-form-5-filed-by-ault-milton-c-iii-6663499)
- 2026-08-04 12:00 UTC [Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending](https://www.quantisnow.com/insight/alzamend-neuro-announces-initial-closing-of-securities-purchase-agreement-with-6661204)
- 2026-08-03 20:30 UTC [SEC Form 8-K] [Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alzamend-neuro-inc-filed-sec-form-8-k-entry-into-a-6660103)
- 2026-07-22 20:30 UTC [SEC Form 10-K] [SEC Form 10-K filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-alzamend-neuro-inc-6645512)
- 2026-07-21 20:30 UTC [SEC Form 8-K] [Alzamend Neuro Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alzamend-neuro-inc-filed-sec-form-8-k-other-events-financial-6644005)
- 2026-04-17 20:30 UTC [SEC Form 8-K] [Alzamend Neuro Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alzamend-neuro-inc-filed-sec-form-8-k-submission-of-matters-6504999)
- 2026-04-16 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Ault Milton C Iii](https://www.quantisnow.com/insight/sec-form-4-filed-by-ault-milton-c-iii-6503391)
- 2026-04-07 12:00 UTC [Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital](https://www.quantisnow.com/insight/alzamend-neuro-reports-encouraging-pharmacodynamic-data-from-phase-ii-clinical-6490405)
- 2026-03-26 12:00 UTC [Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions](https://www.quantisnow.com/insight/alzamend-neuro-reports-positive-topline-data-from-phase-ii-clinical-6470022)
- 2026-03-20 20:30 UTC [SEC Form 8-K] [Alzamend Neuro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alzamend-neuro-inc-filed-sec-form-8-k-notice-of-delisting-6463432)
- 2026-03-16 12:00 UTC [Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital](https://www.quantisnow.com/insight/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001-lithium-6448318)
- 2026-03-11 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-alzamend-neuro-inc-6442334)
- 2026-03-06 21:46 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-alzamend-neuro-inc-6435287)
- 2026-03-06 21:30 UTC [SEC Form 8-K] [Alzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/alzamend-neuro-inc-filed-sec-form-8-k-entry-into-a-6435133)
- 2026-02-26 22:12 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-alzamend-neuro-inc-6417042)
- 2026-02-26 22:12 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-alzamend-neuro-inc-6417041)
- 2026-02-09 21:30 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Alzamend Neuro Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-alzamend-neuro-inc-6382034)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ALZN
- Earnings history: https://www.quantisnow.com/earnings/ALZN
- Dividend history: https://www.quantisnow.com/dividends/ALZN
- Insider transactions: https://www.quantisnow.com/insiders/ALZN
- Options chain: https://www.quantisnow.com/options/ALZN
- SEC 8-K filings only: https://www.quantisnow.com/company/ALZN/8-k
- RSS and alerts for ALZN: https://www.quantisnow.com/docs/rss-feeds.md
